This is a review of the 52-week efficacy and safety results of the SPIRIT head-to-head study of ixekizumab vs adalimumab in patients with psoriatic arthritis.
The study involved over 566 patients. Commentary is provided by Associate Professor Andrew Östör, a consultant rheumatologist at Cabrini Medical Centre and researcher at Emeritus Research, Melbourne, Australia.
Please login below to download this issue (PDF)